Mounjaro and Zepbound are driving an unprecedented 48% top-line expansion, catapulting Eli Lilly past a $1.1T market cap. Yet the stock demands absolute perfection: does the GLP-1 pricing curve mirror a winner-take-all tech monopoly, or a traditional pharmaceutical commodity? Four analyst lenses, three scenarios, four time horizons.
Gray line = Eli Lilly's actual price into today ($784 low Oct ’25 → $1,293 peak Aug ’26 → $1,257 now); colored paths = synthesized scenario midpoints forward, probability-weighted (base 50% · bull 25% · bear 25%). Log-linear, mid-year marks. Wall Street 12-month consensus ≈ $1,315 (range $830–$1,600, “Moderate Buy” rating).
Those probabilities are a judgment call — so make them yours. Drag to set how likely the bear and bull cases are (base takes the remainder); the blended target below, the dotted line on the chart, and the prob-weighted row of the scenario cards all update live.
The same clinical outcomes support wildly different valuations depending on which analytical framework you trust. Each lens below is a synthesized expert perspective.
A $1.1T company growing the top line at 48% is structurally unprecedented. GLP-1 is the biggest total addressable market in pharmaceutical history, effectively acting as foundational cardiovascular, apnea, and obesity prevention. With Retatrutide (triple-G) and Orforglipron (oral) approaching, Lilly maintains best-in-class efficacy. The 30–40% EPS compounding deserves a premium, software-like multiple.
While trailing free cash flow sits at an impressive $18.2B, the FCF yield is a measly ~1.6% due to the $1.1T market cap. Worse, capital expenditures are exploding (approaching $10B+/yr) to build out the manufacturing footprint. At a ~43x TTM P/E, any hiccup in pricing power from looming competition will compress the multiple violently. Great business, zero margin of safety.
Volume growth is currently masking aggressive price deterioration (international realized prices dropped 36% recently). By 2027-2028, the supply shortage will end. Competitors like Amgen, Viking, and Roche will enter. PBMs will use the newfound supply to brutally squeeze net realized prices, transforming a "winner-take-all" software-like margin into a standard, decaying pharma commodity.
The true moat isn't just the molecule; it's the $20B+ head start in physical manufacturing capacity that prevents challengers from scaling. Furthermore, Alzheimer's (Kisunla) and immunology (Ebglyss, +131% YoY) provide billions in diversified, non-incretin revenue. The market is underestimating how sticky the "first-mover" advantage is in chronic weight management.
What the sell-side expects over the next year. Bars are sorted low to high; the dashed line is today's $1,257.03.
Sell-side 12-month targets. The consensus is roughly $1,315, indicating caution among some analysts regarding near-term valuation ceilings, though the rating distribution remains heavily skewed toward "Buy". The dashed line marks today's $1,257.03. Firms, ratings, and targets illustrative.
Synthesized scenario midpoints (mid-year). Returns shown vs. today's $1,257.03. These are illustrative frameworks based on pipeline execution and margin durability, not predictions with certainty.
Where the money actually goes. The staggering physical moat — nearly $10B in annual capacity build-out — protects the top line, but at high capital intensity.
Lilly's financial trajectory mirrors early hyper-growth tech, though structurally tied to the physical world. Revenue (sky) is exploding alongside Mounjaro/Zepbound adoption, driving an inflection in free cash flow (olive). However, capital expenditures (clay) have climbed to nearly $10B+ annually to solve the GLP-1 supply shortage. Total debt (slate) remains highly manageable. Figures illustrative; 2026E reflects guidance midpoint.
The multi-thousand-dollar targets are built on the assumption that Lilly will generate software-like EPS compounding. Here is the earnings ladder beneath the base case.
Adjusted (non-GAAP) EPS. The 2026 estimate reflects Lilly's raised full-year guidance midpoint ($35.50 to $36.50). The base case expects earnings to compound materially through the end of the decade as margins expand, reaching nearly $100 per share by 2031. This EPS ladder times a ~25x exit multiple gives the $2,000 base-case target.
Q2 2026, year-over-year — illustrating the absolute dominance of the core incretin franchise alongside new frontier approvals.
Every major operating line is accelerating. Total revenue up 48% to $23.0B, anchored by Mounjaro approaching a $40B run-rate. The core profitability metrics (olive) prove that scale is translating to the bottom line (Net income +72%), while frontier segments like immunology (Ebglyss) outpace even the headline GLP-1s, albeit from a smaller base.
The entire valuation argument compresses into one disagreement: does the GLP-1 franchise behave like a winner-take-all software platform, or a traditional pharmaceutical curve where supply destroys price?
Where each risk sits along the clinical and commercial pathway. Note that the most existential risks (pricing compression) are highly likely as the supply-demand imbalance normalizes.
As supply constraints ease and Amgen/Viking enter, pharmacy benefit managers will aggressively negotiate down the net realized price per prescription.
Executing $10B+ in annual global capex faces inevitable delays, temporarily limiting volume growth while competitors catch up.
A rival (e.g., Amgen's MariTide or a Novo multi-agonist) achieves dramatically better muscle-preservation or dosing schedules, stealing market share.
A severe, previously unseen side effect emerges after years of mass, chronic use (e.g., severe GI paralysis or lean mass depletion), halting adoption.
CMS or legislative action forces mandatory price caps on blockbuster obesity/diabetes medications due to budget strain.
Clinical setbacks in Alzheimer's (Kisunla) or immunology fail to diversify the revenue base, increasing dependence on incretins.
Inclusion in national health systems (e.g., China's NRDL) drives massive volume but slashes per-unit revenue (already -36% in Q2).
Hover the dotted terms in the metrics, or scan the desk's working definitions here.